(Q43296477)

English

Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects

scientific article published in January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 November 2017

Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects (English)

1 reference

Europe PubMed Central

18 November 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

Sanjeev Kumar Sharma

7

1 reference

Europe PubMed Central

18 November 2017

author name string

Kumar P Chandra

1

1 reference

Europe PubMed Central

18 November 2017

Ajay Shiwalkar

2

1 reference

Europe PubMed Central

18 November 2017

Jignesh Kotecha

3

1 reference

Europe PubMed Central

18 November 2017

Purav Thakkar

4

1 reference

Europe PubMed Central

18 November 2017

Ambrish Srivastava

5

1 reference

Europe PubMed Central

18 November 2017

Vijay Chauthaiwale

6

1 reference

Europe PubMed Central

18 November 2017

Maurice R Cross

8

1 reference

Europe PubMed Central

18 November 2017

Chaitanya Dutt

9

1 reference

Europe PubMed Central

18 November 2017

publication date

1 January 2009

1 reference

Europe PubMed Central

18 November 2017

Clinical Drug Investigation

1 reference

Europe PubMed Central

18 November 2017

29

1 reference

Europe PubMed Central

18 November 2017

9

1 reference

Europe PubMed Central

18 November 2017

559-575

1 reference

Europe PubMed Central

18 November 2017

Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats

1 reference

https://api.crossref.org/works/10.2165%2F11315260-000000000-00000

21 January 2018

Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical review: The role of advanced glycation end products in progression and complications of diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

How hyperglycemia promotes atherosclerosis: molecular mechanisms

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Breakers of advanced glycation end products restore large artery properties in experimental diabetes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TRC4149 a novel advanced glycation end product breaker improves hemodynamic status in diabetic spontaneously hypertensive rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advanced glycation end products and diabetic complications: a general overview.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advanced glycation end products and cardiovascular disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial dysfunction in diabetic cardiomyopathy: pathogenesis and potential treatment targets.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19663519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11315260-000000000-00000

1 reference

Europe PubMed Central

18 November 2017

1 reference

Europe PubMed Central

18 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43296477&oldid=2143885233"